Highlights the significant risk of fatal hemorrhage associated with dicumarol use, especially in the absence of adequate laboratory monitoring.
REPORTS of deaths due to hemorrhagic diatheses resulting from the use of bishydroxycoumarin U. S. P. (dicumarol) have been accumulating in the literature. Since the drug became available in 1941, overly enthusiastic reports leading to its general use prophylactically and therapeutically, coupled with the lack of adequate laboratory tests for its control, have resulted in an increased number of reported and unreported fatalities. The recent publications of Lilly and Lee,¹in which five deaths were recorded, as well as Duff and Shull's²résumé of 23 deaths resulting from the use of dicumarol have focused attention on this problem. One notes additional examples of fatalities such as the two deaths in Arthur Allen's³series and one in Gross's⁴series on vascular grafts. There are undoubtedly many more unpublished cases in smaller hospitals and in general practice. De Takats'⁵recent report is not in agreement with the
No takes yet. Share an insight, caveat, or question.
Louis T. Wright (1951) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: